Chengdu Brilliant Biopharmaceutical

Chengdu Brilliant Biopharmaceutical is a clinical-stage biotechnology company based in Chengdu, China, specializing in the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory disorders. The company's research focus is primarily centered on the Janus kinase (JAK) family, with a lead program targeting Tyrosine Kinase 2 (TYK2) to provide highly selective and safer treatment options. Their flagship candidate, B-001, is currently in Phase 2 clinical trials for psoriasis, demonstrating the company's ability to transition from internal discovery to clinical validation. Operating out of the Tianfu International Bio-town, Chengdu Brilliant Biopharmaceutical leverages its proprietary R&D platform to build a pipeline of first-in-class and best-in-class oral drugs. The company aims to address significant unmet medical needs in the global immunology market by delivering effective alternatives to existing biologic and systemic therapies.